Exelixis Stock Falls on Merck's Rival Drug Trial Success

Key Summary of Stock Performance

Exelixis Inc. (NASDAQ:EXEL) shares experienced a significant decline, closing down 6.6% on Monday. The drop was a direct reaction to competitor Merck announcing superior results from a late-stage trial for its kidney cancer combination therapy.

Overview of Clinical Trial Data

Merck's LITESPARK-011 trial showed that its dual oral regimen of WELIREG and LENVIMA outperformed Exelixis's monotherapy, Cabometyx. According to the data, Merck's therapy demonstrated a statistically significant improvement, reducing the risk of disease progression or death by 30% compared to Cabometyx in patients with advanced renal cell carcinoma.

Impact on the Market

The market responded swiftly, with Exelixis shares falling as much as 9.9% intraday, the largest drop since October. Analysts from firms including RBC Capital Markets and Stifel view the results as a major competitive threat to Exelixis's key Cabometyx franchise. Consequently, RBC lowered its price target on EXEL, citing pressure on its second-line treatment market share.

Future Outlook

The trial results introduce new complexity to the treatment algorithm for renal cell carcinoma. This development is expected to create headwinds for Cabometyx sales and market position, as Merck's more effective therapy progresses toward regulatory approval and market entry.

FAQ

Q: Why did Exelixis (EXEL) stock drop significantly?
A: The stock fell because competitor Merck's combination therapy proved 30% more effective at reducing disease progression or death than Exelixis's drug, Cabometyx, in a late-stage kidney cancer trial.

Q: What is the name of Merck's competing therapy?
A: Merck's therapy is a combination of two oral drugs: WELIREG (belzutifan) and LENVIMA (lenvatinib).

Source: Investing.com